The National Commission into the Regulation of AI in Healthcare published its recommendations.

The National Commission into the Regulation of AI in Healthcare published its recommendations.

10-09-2026

Regulatory

This is for a specific reader. Post-seed, AI, building in a regulated market. Burning £75k to £110k a month. Six to eighteen months of runway left. If that's not you, this will still make sense, it just won't sting the same way.

The National Commission into the Regulation of AI in Healthcare published its recommendations this week. Twelve months of evidence, over 12,000 respondents, the largest engagement of its kind ever run in the UK on healthcare technology regulation. Most coverage is written for patients and clinicians. Here is what it means for your runway.

1 Staged authorisation is coming, not a single approval gate. Build a provisional phase into your timeline and your pricing, not one yes or no moment.

2 Post-market surveillance becomes a standing operational cost, not a launch expense you pay once and forget.

3 You will be contractually required to name who owns each risk control before deployment. "Someone else is handling that" stops being an assumption and becomes a named line in a contract.

4 A dependency on a foundation model must be disclosed, with a continuity plan, in your regulatory submission and your procurement contracts. If you sit on GPT or Claude, this is now your problem to answer for, not a footnote.

5 An opt-in "Master File" pathway is forming for products built on shared foundation models. Worth watching if that is your architecture.

6 NHS Trusts will get a formal AI-readiness self-assessment. If your buyer cannot pass it, your deal stalls regardless of how good your product is.

7 Enforcement is getting real teeth, financial penalties for non-compliance. Your already-cautious buyer just got a harder reason to be more cautious.

8 A "classification confirmation" service may let you get a written regulatory determination early, if built. Worth tracking, it could shorten the ambiguity that eats months of runway.

9 Patients get an explicit right to know AI is used in their care, with an opt-out. A new conversation your buyer will expect you to have an answer for.
None of this is law yet. A government response follows separately. But it is the direction of travel, and building against where the puck is going, not where it is, is the whole game.

Next week I'm writing three pieces, one for each of the takeaways above that will cost founders the most if they miss it. The contract clause that just made "someone else owns that" a fireable assumption. The readiness check your buyer might fail before you ever get in the room. And what it means that the government just put a name on the thing I've been calling Platform Dependency Debt.

If any of the ten above made you pause, you already know which one is coming for you first.

I map patterns like these across thirteen categories of untested assumption for AI founders in regulated markets. Worth a look before the next one catches you out: https://lnkd.in/gZgRmHgu